Highlights on the appropriate use of fluoroquinolones in respiratory tract infections

Pulmonary Pharmacology and Therapeutics

Volumn 19, Issue SUPPL. 1, 2006, Pages 11-19

  Blasi, Francesco ^a   Tarsia, Paolo ^a   Aliberti, Stefano ^a   Santus, PierAchille ^b   Allegra, Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

Author keywords

Antimicrobial resistance; Community acquired respiratory infections; Fluoroquinolones

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; DIGOXIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SITAFLOXACIN; STREPTOGRAMIN; THEOPHYLLINE; WARFARIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW;

ANTI-INFECTIVE AGENTS; BACTERIA; BRONCHITIS, CHRONIC; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 30344435869     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2005.09.008     Document Type: Review

References (64)

1. J. Mitsuyama Structures of existing and new quinolones and relationship to bactericidal activity against Streptococcus pneumoniae J Antimicrob Chemother 44 1999 201 207
2. F.J. Schmitz, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, and M. Klootwijk Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus J Antimicrob Chemother 41 1998 481 484
3. S.K. Chant, M. Singh, and N.R. Chatterjee The chemical and biological aspects of fluoroquinolones: reality and dreams Curr Pharm Design 7 2001 313 337
4. G. Prats, C. Roig, E. Miro, F. Navarro, and B. Mirelis In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones Eur J Clin Microbiol Infect Dis 21 2002 328 334
5. S.J. Keam, and C.M. Perry Prulifloxacin Drugs 64 19 2004 2221 2234
6. S.C. Chien, A.T. Chow, and J. Natarajan Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects Antimicrob Agents Chemother 41 1997 1562 1565
7. C.H. Nightingale Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics Pharmacotherapy 20 2000 245 256
8. Y. Dong, X. Zhao, and B. Kreiswirth Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis Antimicrob Agents Chemother 44 2000 1756 1758
9. J. Blondeau, X. Zhao, and G. Hansen Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 433 438
10. A. Dalhoff, and F.J. Schmitz In vitro antibacterial activity and pharmacodynamics of new quinolones Eur J Clin Microbiol Infect Dis 22 2003 203 221
11. D.J. Hoban, S.K. Bouchillon, J.L. Johnson, G.G. Zanhel, D.L. Butler, and L.A. Miller Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study Eur J Clin Microbiol Infect Dis 20 2001 814 819
12. D. Milatovich, F.J. Schmitz, S. Brisse, J. Verhoef, and A.C. Fluit In vitro activities of sitafloxacin and six other quinolones against 8.796 clinical bacterial isolates Antimicrob Agents Chemother 44 2000 1102 1107
13. M.P. Montanari, M. Mingoia, and P.E. Varaldo In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates Antimicrob Agents Chemother 45 2001 3616 3622
14. D.C. Hooper Emerging mechanisms of fluoroquinolone resistance Emerg Infect Dis 7 2001 337 341
15. F.J. Boswell, J.M. Andrews, G. Jevons, and R. Wise Comparison of in vitro activities of several new quinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J Antimicrob Chemother 50 2002 495 502
16. H. Bolhuis, H.W. Vav Veen, B. Poolman, and A.J. Driessen Mechanisms of multidrug transporters FEMS Microbiol Rev 21 1997 55 84
17. L. Martìnez-Martìnez, A. Pascual, and G.A. Jacoby Quinolone resistance from a transferable plasmid Lancet 351 1998 797 799
18. K. Drilica A strategy for fighting antibiotic resistance ASM News 67 2001 27 33
19. W.M. Scheld Maintaining fluoroquinolone class efficacy: review of influencing factors Emerg Infect Dis 9 2003 1 9
20. P.L. Ho, R.W. Yung, D.N. Tsang, T.L. Que, M. Ho, and W.H. Seto Increasing resistance of S. pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000 J Antimicrob Chemother 48 2001 659 665
21. G.V. Doern, K.P. Heilmann, H.K. Huynh, P.L. Rhomberg, S.L. Coffman, and A.B. Brueggemann Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance since 1994-1995 Antimicrob Agents Chemother 45 2001 1721 1729
22. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 152 1995 S77 S121
23. S. Sethi, N. Evans, B.J. Grant, and T.F. Murphy New strains of bacteria and exacerbations of chronic obstructive pulmonary disease N Engl J Med 347 2002 465 471
24. P. Ball, and B. Make Acute exacerbations of chronic bronchitis: an international comparison Chest 113 Suppl 3 1998 199S 204S
25. A. McGuire, D.E. Irwin, and P. Fenn The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales Value Health 4 2001 370 375
26. N.R. Anthonisen, J. Manfreda, C.P. Warren, E.S. Hershfields, G.K. Harding, and N.A. Nelson Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease Ann Intern Med 106 1987 196 204
27. S. Sethi Infectious exacerbations of chronic bronchitis: diagnosis and management J Antimicrob Chemother 43 Suppl A 1999 97 105
28. Guidelines for the clinical management of COPD Exacerbations/acute respiratory failure: antibiotherapy Rev Mal Respir 20 3 Part 2 2003 S65 S68 (in French)
29. B.I. Davies, and F.P. Maesen Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity J Antimicrob Chemother 43 Suppl C 1999 83 90
30. C.A. De Abate, M. Russel, and P. McElvaine Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis Respir Care 42 1997 206 213
31. M.P. Habib, M. Russell, and C.A. De Abate Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in the treatment of acute exacerbations of chronic bronchitis Infect Dis Clin Practice 7 1998 1 9
32. P.M. Shah, F.P. Maesen, and A. Dolmann Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of a randomized, double-blind study J Antimicrob Chemother 43 1999 529 539
33. L.R. Weiss Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis Clin Ther 24 2002 1414 1425
34. Lode H, Eller J, Linnhoff A, Ioanas M. The Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 2004; 24:947-53.
35. A. Ramirez, J. Molina, and A. Hofinann Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: clinical trial results J Respir Dis 20 11 1999 30s 39s
36. C.A. De Abate, R.A. Mclvor, and P. McElvaine Gatifloxacin vs. cefuroxime axetil in patients with acute exacerbations of chronic bronchitis J Respir Dis 20 11 1999 23s 29s
37. R. Wilson, R. Kubin, and I. Ballin Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis J Antimicrob Chemother 44 1999 501 513
38. S. Chodosh, C.A. De Abate, and D. Haverstock Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis The Bronchitis Study Group. Respir Med 94 2000 18 27
39. S. Kreis, N. Herrera, and N. Golzar A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis JCOM 7 2000 333 337
40. C.A. De Abate, C.P. Matthew, and J.H. Warner The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis Respir Med 94 2000 1029 1037
41. T. Schaberg, I. Ballin, and G. Huchon A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbations of chronic bronchitis J Int Med Res 29 2001 314 328
42. J. Lorenz, I.M. Thate-Waschke, and O. Mast Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective J Int Med Res 29 2001 74 86
43. R. Wilson, L. Allegra, and G. Huchon Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis Chest 125 2004 953 964
44. R. Wilson, C. Langan, P. Ball, K. Bateman, and R. Pypstra Oral gemifloxacin once daily for five days compared with sequential therapy with IV ceftriaxone/oral cefuroxime (max of 10 days) in the treatment of hospitalised patients with acute exacerbations of chronic bronchitis Respir Med 97 2003 242 249
45. S. Sethi, C. Fogarty, and A. Fulambarker A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis Respir Med 98 2004 697 707
46. C. Grassi, E. Salvatori, M.T. Rosignoli, and P. Dionisio Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis Respiration 69 2002 217 222
47. T.M. File, J. Segreti, and L. Dubar A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia Antimicrob Agents Chemother 41 1997 1965 1972
48. A.M. Geddes, M. Thaler, and S. Schonwald Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomised trial J Antimicrob Chemother 44 1999 799 810
49. J. Sullivan, A.D. McElroy, and R.W. Honsinger Treating community-acquired pneumonia with once daily gatifloxacin vs. once daily levofloxacin J Respir Dis 20 S11 1999 49s 59s
50. J.A. Ramirez, T.H. Nguyen, and G. Tellier Treating community-acquired pneumonia with once daily gatifloxacin vs. twice daily clarithromycin J Respir Dis 20 S11 1999 40s 48s
51. C. Fogarty, M.E. Dowell, and W.T. Ellison Treating community-acquired pneumonia in hospitalised patients: gatifloxacin vs ceftriaxone/clarithromycin J Respir Dis 20 S11 1999 S60 S69
52. L.D. Dresser, M.S. Niederman, and J.A. Paladino Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia Chest 119 2001 1439 1448
53. C. Fogarty, C. Grossman, and J. Williams Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia Infect Med 16 1999 748 763
54. G. Hoeffken, H.P. Meyer, and J. Winter The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia Respir Med 95 2001 553 564
55. P. Petitpretz, P. Arvis, and M. Marcel Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults Chest 119 2001 185 195
56. R. Finch, D. Schurmann, O. Collins, R. Kubin, J. McGivern, and H. Bobbaers Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment Antimicrob Agents Chemother 46 2002 1746 1754
57. M. Zervos, L.A. Mandell, P.S. Vrooman, C.P. Andrews, A. Mclvor, and R.H. Abdulla Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia Treat Respir Med 3 2004 329 336
58. H. Lode, T.M. File, L.A. Mandell, P. Ball, R. Pypstra, and M. Thomas Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalised with community-acquired pneumonia: randomized, open label, multicenter study of clinical efficacy and tolerability Clin Ther 24 2002 1915 1936
59. J.M. Legg, and A.J. Bint Will pneumococci put quinolones in their place J Antirmcrob Chemother 44 1999 425 427
60. D.K. Chen, A. McGeer, J.C. de Azavedo, and D.E. Low Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada New Engl J Med 341 1999 233 239
61. G.G. Zhanel, K. Emis, and L. Vercainge A critical review of the fluoroquinolones: focus on respiratory tract infections Drugs 62 2002 13 59
62. M.S. Niederman Guidelines for the management of community-acquired pneumonia Med Clin N Am 85 2001 1493 1509
63. American Thoracic Society Documents Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
64. M.M. Neuhauser, R.A. Weinstein, R. Rydman, L.H. Danziger, G. Karam, and J.P. Quinn Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use JAMA 289 2003 885 888